The scientific potential of antibody-drug conjugates has been proven by the two approved ADCs on the market, and the 50+ ongoing clinical trials. So despite the recent disappointing announcements coming out from the clinic, the antibody-drug conjugates field is not perturbed. Instead, for those companies staying for the long haul, it means they have to think outside the box. These companies are taking the learnings from the clinic to heart, and exploring new paradigms such as small molecule-drug conjugates, natural products as warheads, multiple payloads, higher DAR, next-generation conjugation chemistries and other novel approaches. At ADCs: New Ligands, Payloads and Chemistry, we invite scientists to present their new technologies and showcase how they are re-defining the rules in the field of ADCs.

Topics to be discussed include but are not limited to:

  • Small Molecule-Drug Conjugate
  • New Targeting Ligands – Fabs, Scfv, Peptides
  • Natural Products as Warheads
  • Dual Warheads
  • Novel Targets Beyond Tubulin
  • New and Multiple Payloads
  • Internalization Challenges
  • Managing Hydrophobicity
  • Breaking The Rule of DAR 4
  • Next-Generation Chemistry for Improved Conjugation and Linker Stability
  • Combination of ADC with Immuno-modulators
  • Characterization of ADCs
  • Engineering ADCs for Developability, Enhanced Specificity and Binding, and Reduced Toxicity

Scientists who wish to present their knowledge and expertise to their colleagues are asked to click here to submit an abstract. Remember to specify the conference that you are interested in and please provide your full contact information.

The deadline for submission is Friday, September 25, 2015.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:

For partnering and sponsorship information, please contact:

Mimi Langley
Senior Conference Director
T: 816 472 0701

Jason Gerardi
(Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: 781-972-5452

Carol Dinerstein
(Companies L-Z)
Director, Business Development
Cambridge Healthtech Institute
T: 781.972.5471